Treating type 2 diabetes in COVID-19 patients: the potential benefits of injective therapies.
Identifieur interne : 000039 ( Main/Exploration ); précédent : 000038; suivant : 000040Treating type 2 diabetes in COVID-19 patients: the potential benefits of injective therapies.
Auteurs : Miriam Longo [Italie] ; Paola Caruso [Italie] ; Maria Ida Maiorino [Italie] ; Giuseppe Bellastella [Italie] ; Dario Giugliano [Italie] ; Katherine Esposito [Italie]Source :
- Cardiovascular diabetology [ 1475-2840 ] ; 2020.
Descripteurs français
- KwdFr :
- Appréciation des risques (MeSH), Betacoronavirus (pathogénicité), Diabète de type 2 (diagnostic), Diabète de type 2 (sang), Diabète de type 2 (traitement médicamenteux), Diabète de type 2 (épidémiologie), Facteurs de risque (MeSH), Glycémie (effets des médicaments et des substances chimiques), Glycémie (métabolisme), Humains (MeSH), Hypoglycémiants (administration et posologie), Hypoglycémiants (effets indésirables), Incrétines (administration et posologie), Incrétines (effets indésirables), Infections à coronavirus (diagnostic), Infections à coronavirus (thérapie), Infections à coronavirus (virologie), Infections à coronavirus (épidémiologie), Insuline (administration et posologie), Insuline (effets indésirables), Interactions hôte-microbes (MeSH), Marqueurs biologiques (sang), Pandémies (MeSH), Pneumopathie virale (diagnostic), Pneumopathie virale (thérapie), Pneumopathie virale (virologie), Pneumopathie virale (épidémiologie), Prise de décision clinique (MeSH), Récepteur du peptide-1 similaire au glucagon (agonistes), Résultat thérapeutique (MeSH).
- MESH :
- administration et posologie : Hypoglycémiants, Incrétines, Insuline.
- agonistes : Récepteur du peptide-1 similaire au glucagon.
- diagnostic : Diabète de type 2, Infections à coronavirus, Pneumopathie virale.
- effets des médicaments et des substances chimiques : Glycémie.
- effets indésirables : Hypoglycémiants, Incrétines, Insuline.
- métabolisme : Glycémie.
- pathogénicité : Betacoronavirus.
- sang : Diabète de type 2, Marqueurs biologiques.
- thérapie : Infections à coronavirus, Pneumopathie virale.
- traitement médicamenteux : Diabète de type 2.
- virologie : Infections à coronavirus, Pneumopathie virale.
- épidémiologie : Diabète de type 2, Infections à coronavirus, Pneumopathie virale.
- Appréciation des risques, Facteurs de risque, Humains, Interactions hôte-microbes, Pandémies, Prise de décision clinique, Résultat thérapeutique.
English descriptors
- KwdEn :
- Betacoronavirus (pathogenicity), Biomarkers (blood), Blood Glucose (drug effects), Blood Glucose (metabolism), Clinical Decision-Making (MeSH), Coronavirus Infections (diagnosis), Coronavirus Infections (epidemiology), Coronavirus Infections (therapy), Coronavirus Infections (virology), Diabetes Mellitus, Type 2 (blood), Diabetes Mellitus, Type 2 (diagnosis), Diabetes Mellitus, Type 2 (drug therapy), Diabetes Mellitus, Type 2 (epidemiology), Glucagon-Like Peptide-1 Receptor (agonists), Host Microbial Interactions (MeSH), Humans (MeSH), Hypoglycemic Agents (administration & dosage), Hypoglycemic Agents (adverse effects), Incretins (administration & dosage), Incretins (adverse effects), Insulin (administration & dosage), Insulin (adverse effects), Pandemics (MeSH), Pneumonia, Viral (diagnosis), Pneumonia, Viral (epidemiology), Pneumonia, Viral (therapy), Pneumonia, Viral (virology), Risk Assessment (MeSH), Risk Factors (MeSH), Treatment Outcome (MeSH).
- MESH :
- chemical , administration & dosage : Hypoglycemic Agents, Incretins, Insulin.
- chemical , adverse effects : Hypoglycemic Agents, Incretins, Insulin.
- chemical , agonists : Glucagon-Like Peptide-1 Receptor.
- chemical , blood : Biomarkers.
- chemical , drug effects : Blood Glucose.
- chemical , metabolism : Blood Glucose.
- blood : Diabetes Mellitus, Type 2.
- diagnosis : Coronavirus Infections, Diabetes Mellitus, Type 2, Pneumonia, Viral.
- drug therapy : Diabetes Mellitus, Type 2.
- epidemiology : Coronavirus Infections, Diabetes Mellitus, Type 2, Pneumonia, Viral.
- pathogenicity : Betacoronavirus.
- therapy : Coronavirus Infections, Pneumonia, Viral.
- virology : Coronavirus Infections, Pneumonia, Viral.
- Clinical Decision-Making, Host Microbial Interactions, Humans, Pandemics, Risk Assessment, Risk Factors, Treatment Outcome.
Abstract
The coronavirus disease 2019 (COVID-19) has been declared as pandemic by the World Health Organization and is causing substantial morbidity and mortality all over the world. Type 2 diabetes, hypertension, and cardiovascular disease significantly increase the risk for hospitalization and death in COVID-19 patients. Hypoglycemia and hyperglycemia are both predictors for adverse outcomes in hospitalized patients. An optimized glycemic control should be pursued in patients with diabetes and SARS-CoV-2 infection in order to reduce the risk of severe COVID-19 course. Both insulin and GLP-1RAs have shown optimal glucose-lowering and anti-inflammatory effects in type 2 diabetic patients and may represent a valid therapeutic option to treat asymptomatic and non-critically ill COVID-19 diabetic patients.
DOI: 10.1186/s12933-020-01090-9
PubMed: 32698837
PubMed Central: PMC7375203
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Treating type 2 diabetes in COVID-19 patients: the potential benefits of injective therapies.</title><author><name sortKey="Longo, Miriam" sort="Longo, Miriam" uniqKey="Longo M" first="Miriam" last="Longo">Miriam Longo</name><affiliation wicri:level="1"><nlm:affiliation>Division of Endocrinology and Metabolic Diseases, Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Piazza Luigi Miraglia 2, 80138, Naples, Italy. miriam.longo@unicampania.it.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Division of Endocrinology and Metabolic Diseases, Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Piazza Luigi Miraglia 2, 80138, Naples</wicri:regionArea><wicri:noRegion>Naples</wicri:noRegion></affiliation></author><author><name sortKey="Caruso, Paola" sort="Caruso, Paola" uniqKey="Caruso P" first="Paola" last="Caruso">Paola Caruso</name><affiliation wicri:level="1"><nlm:affiliation>Division of Endocrinology and Metabolic Diseases, Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Piazza Luigi Miraglia 2, 80138, Naples, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Division of Endocrinology and Metabolic Diseases, Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Piazza Luigi Miraglia 2, 80138, Naples</wicri:regionArea><wicri:noRegion>Naples</wicri:noRegion></affiliation></author><author><name sortKey="Maiorino, Maria Ida" sort="Maiorino, Maria Ida" uniqKey="Maiorino M" first="Maria Ida" last="Maiorino">Maria Ida Maiorino</name><affiliation wicri:level="1"><nlm:affiliation>Diabetes Unit, Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Diabetes Unit, Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples</wicri:regionArea><wicri:noRegion>Naples</wicri:noRegion></affiliation></author><author><name sortKey="Bellastella, Giuseppe" sort="Bellastella, Giuseppe" uniqKey="Bellastella G" first="Giuseppe" last="Bellastella">Giuseppe Bellastella</name><affiliation wicri:level="1"><nlm:affiliation>Division of Endocrinology and Metabolic Diseases, Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Piazza Luigi Miraglia 2, 80138, Naples, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Division of Endocrinology and Metabolic Diseases, Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Piazza Luigi Miraglia 2, 80138, Naples</wicri:regionArea><wicri:noRegion>Naples</wicri:noRegion></affiliation></author><author><name sortKey="Giugliano, Dario" sort="Giugliano, Dario" uniqKey="Giugliano D" first="Dario" last="Giugliano">Dario Giugliano</name><affiliation wicri:level="1"><nlm:affiliation>Division of Endocrinology and Metabolic Diseases, Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Piazza Luigi Miraglia 2, 80138, Naples, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Division of Endocrinology and Metabolic Diseases, Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Piazza Luigi Miraglia 2, 80138, Naples</wicri:regionArea><wicri:noRegion>Naples</wicri:noRegion></affiliation></author><author><name sortKey="Esposito, Katherine" sort="Esposito, Katherine" uniqKey="Esposito K" first="Katherine" last="Esposito">Katherine Esposito</name><affiliation wicri:level="1"><nlm:affiliation>Diabetes Unit, Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Diabetes Unit, Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples</wicri:regionArea><wicri:noRegion>Naples</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32698837</idno><idno type="pmid">32698837</idno><idno type="doi">10.1186/s12933-020-01090-9</idno><idno type="pmc">PMC7375203</idno><idno type="wicri:Area/Main/Corpus">000019</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000019</idno><idno type="wicri:Area/Main/Curation">000019</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000019</idno><idno type="wicri:Area/Main/Exploration">000019</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Treating type 2 diabetes in COVID-19 patients: the potential benefits of injective therapies.</title><author><name sortKey="Longo, Miriam" sort="Longo, Miriam" uniqKey="Longo M" first="Miriam" last="Longo">Miriam Longo</name><affiliation wicri:level="1"><nlm:affiliation>Division of Endocrinology and Metabolic Diseases, Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Piazza Luigi Miraglia 2, 80138, Naples, Italy. miriam.longo@unicampania.it.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Division of Endocrinology and Metabolic Diseases, Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Piazza Luigi Miraglia 2, 80138, Naples</wicri:regionArea><wicri:noRegion>Naples</wicri:noRegion></affiliation></author><author><name sortKey="Caruso, Paola" sort="Caruso, Paola" uniqKey="Caruso P" first="Paola" last="Caruso">Paola Caruso</name><affiliation wicri:level="1"><nlm:affiliation>Division of Endocrinology and Metabolic Diseases, Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Piazza Luigi Miraglia 2, 80138, Naples, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Division of Endocrinology and Metabolic Diseases, Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Piazza Luigi Miraglia 2, 80138, Naples</wicri:regionArea><wicri:noRegion>Naples</wicri:noRegion></affiliation></author><author><name sortKey="Maiorino, Maria Ida" sort="Maiorino, Maria Ida" uniqKey="Maiorino M" first="Maria Ida" last="Maiorino">Maria Ida Maiorino</name><affiliation wicri:level="1"><nlm:affiliation>Diabetes Unit, Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Diabetes Unit, Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples</wicri:regionArea><wicri:noRegion>Naples</wicri:noRegion></affiliation></author><author><name sortKey="Bellastella, Giuseppe" sort="Bellastella, Giuseppe" uniqKey="Bellastella G" first="Giuseppe" last="Bellastella">Giuseppe Bellastella</name><affiliation wicri:level="1"><nlm:affiliation>Division of Endocrinology and Metabolic Diseases, Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Piazza Luigi Miraglia 2, 80138, Naples, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Division of Endocrinology and Metabolic Diseases, Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Piazza Luigi Miraglia 2, 80138, Naples</wicri:regionArea><wicri:noRegion>Naples</wicri:noRegion></affiliation></author><author><name sortKey="Giugliano, Dario" sort="Giugliano, Dario" uniqKey="Giugliano D" first="Dario" last="Giugliano">Dario Giugliano</name><affiliation wicri:level="1"><nlm:affiliation>Division of Endocrinology and Metabolic Diseases, Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Piazza Luigi Miraglia 2, 80138, Naples, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Division of Endocrinology and Metabolic Diseases, Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Piazza Luigi Miraglia 2, 80138, Naples</wicri:regionArea><wicri:noRegion>Naples</wicri:noRegion></affiliation></author><author><name sortKey="Esposito, Katherine" sort="Esposito, Katherine" uniqKey="Esposito K" first="Katherine" last="Esposito">Katherine Esposito</name><affiliation wicri:level="1"><nlm:affiliation>Diabetes Unit, Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Diabetes Unit, Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples</wicri:regionArea><wicri:noRegion>Naples</wicri:noRegion></affiliation></author></analytic><series><title level="j">Cardiovascular diabetology</title><idno type="eISSN">1475-2840</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Betacoronavirus (pathogenicity)</term><term>Biomarkers (blood)</term><term>Blood Glucose (drug effects)</term><term>Blood Glucose (metabolism)</term><term>Clinical Decision-Making (MeSH)</term><term>Coronavirus Infections (diagnosis)</term><term>Coronavirus Infections (epidemiology)</term><term>Coronavirus Infections (therapy)</term><term>Coronavirus Infections (virology)</term><term>Diabetes Mellitus, Type 2 (blood)</term><term>Diabetes Mellitus, Type 2 (diagnosis)</term><term>Diabetes Mellitus, Type 2 (drug therapy)</term><term>Diabetes Mellitus, Type 2 (epidemiology)</term><term>Glucagon-Like Peptide-1 Receptor (agonists)</term><term>Host Microbial Interactions (MeSH)</term><term>Humans (MeSH)</term><term>Hypoglycemic Agents (administration & dosage)</term><term>Hypoglycemic Agents (adverse effects)</term><term>Incretins (administration & dosage)</term><term>Incretins (adverse effects)</term><term>Insulin (administration & dosage)</term><term>Insulin (adverse effects)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (diagnosis)</term><term>Pneumonia, Viral (epidemiology)</term><term>Pneumonia, Viral (therapy)</term><term>Pneumonia, Viral (virology)</term><term>Risk Assessment (MeSH)</term><term>Risk Factors (MeSH)</term><term>Treatment Outcome (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Appréciation des risques (MeSH)</term><term>Betacoronavirus (pathogénicité)</term><term>Diabète de type 2 (diagnostic)</term><term>Diabète de type 2 (sang)</term><term>Diabète de type 2 (traitement médicamenteux)</term><term>Diabète de type 2 (épidémiologie)</term><term>Facteurs de risque (MeSH)</term><term>Glycémie (effets des médicaments et des substances chimiques)</term><term>Glycémie (métabolisme)</term><term>Humains (MeSH)</term><term>Hypoglycémiants (administration et posologie)</term><term>Hypoglycémiants (effets indésirables)</term><term>Incrétines (administration et posologie)</term><term>Incrétines (effets indésirables)</term><term>Infections à coronavirus (diagnostic)</term><term>Infections à coronavirus (thérapie)</term><term>Infections à coronavirus (virologie)</term><term>Infections à coronavirus (épidémiologie)</term><term>Insuline (administration et posologie)</term><term>Insuline (effets indésirables)</term><term>Interactions hôte-microbes (MeSH)</term><term>Marqueurs biologiques (sang)</term><term>Pandémies (MeSH)</term><term>Pneumopathie virale (diagnostic)</term><term>Pneumopathie virale (thérapie)</term><term>Pneumopathie virale (virologie)</term><term>Pneumopathie virale (épidémiologie)</term><term>Prise de décision clinique (MeSH)</term><term>Récepteur du peptide-1 similaire au glucagon (agonistes)</term><term>Résultat thérapeutique (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Hypoglycemic Agents</term><term>Incretins</term><term>Insulin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Hypoglycemic Agents</term><term>Incretins</term><term>Insulin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="agonists" xml:lang="en"><term>Glucagon-Like Peptide-1 Receptor</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Biomarkers</term></keywords><keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Blood Glucose</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Blood Glucose</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Hypoglycémiants</term><term>Incrétines</term><term>Insuline</term></keywords><keywords scheme="MESH" qualifier="agonistes" xml:lang="fr"><term>Récepteur du peptide-1 similaire au glucagon</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Diabetes Mellitus, Type 2</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Coronavirus Infections</term><term>Diabetes Mellitus, Type 2</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Diabète de type 2</term><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Diabetes Mellitus, Type 2</term></keywords><keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Glycémie</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Hypoglycémiants</term><term>Incrétines</term><term>Insuline</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term><term>Diabetes Mellitus, Type 2</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Glycémie</term></keywords><keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Diabète de type 2</term><term>Marqueurs biologiques</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="thérapie" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Diabète de type 2</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Diabète de type 2</term><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Clinical Decision-Making</term><term>Host Microbial Interactions</term><term>Humans</term><term>Pandemics</term><term>Risk Assessment</term><term>Risk Factors</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Appréciation des risques</term><term>Facteurs de risque</term><term>Humains</term><term>Interactions hôte-microbes</term><term>Pandémies</term><term>Prise de décision clinique</term><term>Résultat thérapeutique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The coronavirus disease 2019 (COVID-19) has been declared as pandemic by the World Health Organization and is causing substantial morbidity and mortality all over the world. Type 2 diabetes, hypertension, and cardiovascular disease significantly increase the risk for hospitalization and death in COVID-19 patients. Hypoglycemia and hyperglycemia are both predictors for adverse outcomes in hospitalized patients. An optimized glycemic control should be pursued in patients with diabetes and SARS-CoV-2 infection in order to reduce the risk of severe COVID-19 course. Both insulin and GLP-1RAs have shown optimal glucose-lowering and anti-inflammatory effects in type 2 diabetic patients and may represent a valid therapeutic option to treat asymptomatic and non-critically ill COVID-19 diabetic patients.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32698837</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>29</Day></DateCompleted><DateRevised><Year>2020</Year><Month>07</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1475-2840</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>07</Month><Day>22</Day></PubDate></JournalIssue><Title>Cardiovascular diabetology</Title><ISOAbbreviation>Cardiovasc Diabetol</ISOAbbreviation></Journal><ArticleTitle>Treating type 2 diabetes in COVID-19 patients: the potential benefits of injective therapies.</ArticleTitle><Pagination><MedlinePgn>115</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12933-020-01090-9</ELocationID><Abstract><AbstractText>The coronavirus disease 2019 (COVID-19) has been declared as pandemic by the World Health Organization and is causing substantial morbidity and mortality all over the world. Type 2 diabetes, hypertension, and cardiovascular disease significantly increase the risk for hospitalization and death in COVID-19 patients. Hypoglycemia and hyperglycemia are both predictors for adverse outcomes in hospitalized patients. An optimized glycemic control should be pursued in patients with diabetes and SARS-CoV-2 infection in order to reduce the risk of severe COVID-19 course. Both insulin and GLP-1RAs have shown optimal glucose-lowering and anti-inflammatory effects in type 2 diabetic patients and may represent a valid therapeutic option to treat asymptomatic and non-critically ill COVID-19 diabetic patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Longo</LastName><ForeName>Miriam</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-6459-5854</Identifier><AffiliationInfo><Affiliation>Division of Endocrinology and Metabolic Diseases, Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Piazza Luigi Miraglia 2, 80138, Naples, Italy. miriam.longo@unicampania.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caruso</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Division of Endocrinology and Metabolic Diseases, Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Piazza Luigi Miraglia 2, 80138, Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maiorino</LastName><ForeName>Maria Ida</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>Diabetes Unit, Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bellastella</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Endocrinology and Metabolic Diseases, Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Piazza Luigi Miraglia 2, 80138, Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giugliano</LastName><ForeName>Dario</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Endocrinology and Metabolic Diseases, Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Piazza Luigi Miraglia 2, 80138, Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Esposito</LastName><ForeName>Katherine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Diabetes Unit, Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cardiovasc Diabetol</MedlineTA><NlmUniqueID>101147637</NlmUniqueID><ISSNLinking>1475-2840</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000593833">GLP1R protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000067757">Glucagon-Like Peptide-1 Receptor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054795">Incretins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007328">Insulin</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName><SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName><QualifierName UI="Q000472" MajorTopicYN="Y">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001786" MajorTopicYN="N">Blood Glucose</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000066491" MajorTopicYN="N">Clinical Decision-Making</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000067757" MajorTopicYN="N">Glucagon-Like Peptide-1 Receptor</DescriptorName><QualifierName UI="Q000819" MajorTopicYN="N">agonists</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000076662" MajorTopicYN="N">Host Microbial Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="N">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054795" MajorTopicYN="N">Incretins</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">COVID-19</Keyword><Keyword MajorTopicYN="Y">Cytokine storm</Keyword><Keyword MajorTopicYN="Y">GLP-1RAs</Keyword><Keyword MajorTopicYN="Y">Hyperglycemia</Keyword><Keyword MajorTopicYN="Y">Insulin</Keyword><Keyword MajorTopicYN="Y">Type 2 diabetes</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>05</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>07</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32698837</ArticleId><ArticleId IdType="doi">10.1186/s12933-020-01090-9</ArticleId><ArticleId IdType="pii">10.1186/s12933-020-01090-9</ArticleId><ArticleId IdType="pmc">PMC7375203</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lancet. 2020 Apr 11;395(10231):1225-1228</Citation><ArticleIdList><ArticleId IdType="pubmed">32178769</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Diabetes Endocrinol. 2020 Jun;8(6):546-550</Citation><ArticleIdList><ArticleId IdType="pubmed">32334646</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes Care. 2020 Jul;43(7):1427-1432</Citation><ArticleIdList><ArticleId IdType="pubmed">32409501</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Mar 28;395(10229):1054-1062</Citation><ArticleIdList><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>J Microbiol Immunol Infect. 2020 Jun;53(3):454-458</Citation><ArticleIdList><ArticleId IdType="pubmed">32205091</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardiovasc Diabetol. 2019 Jun 4;18(1):72</Citation><ArticleIdList><ArticleId IdType="pubmed">31164120</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardiovasc Diabetol. 2019 Jun 6;18(1):73</Citation><ArticleIdList><ArticleId IdType="pubmed">31167654</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardiovasc Diabetol. 2018 Dec 13;17(1):157</Citation><ArticleIdList><ArticleId IdType="pubmed">30545359</ArticleId></ArticleIdList></Reference><Reference><Citation>Cytokine Growth Factor Rev. 2020 Jun;53:38-42</Citation><ArticleIdList><ArticleId IdType="pubmed">32360420</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2020 Apr 22;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32320003</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes Obes Metab. 2019 Nov;21(11):2576-2580</Citation><ArticleIdList><ArticleId IdType="pubmed">31373167</ArticleId></ArticleIdList></Reference><Reference><Citation>Cytokine Growth Factor Rev. 2020 Jun;53:25-32</Citation><ArticleIdList><ArticleId IdType="pubmed">32446778</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes Res Clin Pract. 2019 Aug;154:101-115</Citation><ArticleIdList><ArticleId IdType="pubmed">31238059</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardiovasc Diabetol. 2019 Apr 30;18(1):55</Citation><ArticleIdList><ArticleId IdType="pubmed">31039778</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Endocrinol Metab. 2019 Nov 1;104(11):5274-5284</Citation><ArticleIdList><ArticleId IdType="pubmed">31216011</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Coll Cardiol. 2020 Apr 21;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32330544</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Italie</li></country></list><tree><country name="Italie"><noRegion><name sortKey="Longo, Miriam" sort="Longo, Miriam" uniqKey="Longo M" first="Miriam" last="Longo">Miriam Longo</name></noRegion><name sortKey="Bellastella, Giuseppe" sort="Bellastella, Giuseppe" uniqKey="Bellastella G" first="Giuseppe" last="Bellastella">Giuseppe Bellastella</name><name sortKey="Caruso, Paola" sort="Caruso, Paola" uniqKey="Caruso P" first="Paola" last="Caruso">Paola Caruso</name><name sortKey="Esposito, Katherine" sort="Esposito, Katherine" uniqKey="Esposito K" first="Katherine" last="Esposito">Katherine Esposito</name><name sortKey="Giugliano, Dario" sort="Giugliano, Dario" uniqKey="Giugliano D" first="Dario" last="Giugliano">Dario Giugliano</name><name sortKey="Maiorino, Maria Ida" sort="Maiorino, Maria Ida" uniqKey="Maiorino M" first="Maria Ida" last="Maiorino">Maria Ida Maiorino</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CardioCovidV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000039 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000039 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CardioCovidV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32698837
|texte= Treating type 2 diabetes in COVID-19 patients: the potential benefits of injective therapies.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32698837" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CardioCovidV1
| This area was generated with Dilib version V0.6.35. |  |